All In Biotech

Drug Trial Radar · NCT01186770

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain

Last checked: Nov 19, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 804 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

804

Actual

Start

Sep 1, 2010

Primary completion

Sep 8, 2011

Study completion Sep 8, 2011

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
Collaborators
Progenics Pharmaceuticals, Inc.
First posted
Aug 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in participants with chronic, non-malignant pain.

Conditions

  • Opioid-Induced Constipation

Interventions

  • MethylnaltrexoneDrug

    Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

  • PlaceboDrug

    Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements (RFBMs) Within 4 Hours of Dosing During Weeks 1 to 4Time frame: Weeks 1 to 4

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • PRA International

    Raleigh, North Carolina

  • PRA, Intl.

    Raleigh, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.